LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

CREATE AN ACCOUNT

Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Horsey, Aaron J.; Cox, Megan H.; Sarwat, Sunehera; Kerr, Ian D. (2016)
Publisher: Portland Press Ltd.
Journal: Biochemical Society Transactions
Languages: English
Types: Article
Subjects: 46, 24, ABCG2, ATPase, 4, ABC transporter, Membrane Proteins From A to Z, multidrug pump, pharmacology, Biochemical Society Focused Meetings

Classified by OpenAIRE into

mesheuropmc: sense organs, embryonic structures, animal structures
ABCG2 is one of at least three human ATP binding cassette (ABC) transporters which can facilitate the export from cells of a wide range of chemically unrelated drug molecules. This capacity for multidrug transport is not only a confounding factor in chemotherapy, but is also one of the more perplexing phenomena in transporter biochemistry. Since its discovery in the last decade of the 20th century much has been revealed about ABCG2's localization, physiological function and its broad substrate range. There have also been many investigations of its structure and molecular mechanism. In this mini review article we take a Rumsfeldian approach to ABCG2 and essentially ask what we do know about this transporter, and what we will need to know about this transporter if we wish to use modulation of ABCG2 activity as a therapeutic approach.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 1 Wong, K., Ma, J., Rothnie, A., Biggin, P.C. and Kerr, I.D. (2014) Towards understanding promiscuity in multidrug efflux pumps. Trends Biochem. Sci. 39, 8-16 CrossRef PubMed
    • 2 Mao, Q. and Unadkat, J.D. (2015) Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport - an update. AAPS J. 17, 65-82 CrossRef PubMed
    • 3 Darby, R.A., Callaghan, R. and McMahon, R.M. (2011) P-glycoprotein inhibition; the past, the present and the future. Curr. Drug Metab. 12, 722-731 CrossRef PubMed
    • 4 Jonker, J.W., Buitelaar, M., Wagenaar, E., Van Der Valk, M.A., Scheffer, G.L., Scheper, R.J., Plosch, T., Kuipers, F., Elferink, R.P., Rosing, H. et al. (2002) The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc. Natl. Acad. Sci. U.S.A. 99, 15649-15654 CrossRef PubMed
    • 5 Haider, A.J., Cox, M.H., Jones, N., Goode, A.J., Bridge, K.S., Wong, K., Briggs, D. and Kerr, I.D. (2015) Identification of residues in ABCG2 affecting protein trafficking and drug transport, using co-evolutionary analysis of ABCG sequences. Biosci. Rep. 35, e00241 CrossRef PubMed
    • 6 Aronica, E., Gorter, J.A., Redeker, S., van Vliet, E.A., Ramkema, M., Scheffer, G.L., Scheper, R.J., van der Valk, P., Leenstra, S., Baayen, J.C. et al. (2005) Localization of breast cancer resistance protein (BCRP) in microvessel endothelium of human control and epileptic brain. Epilepsia 46, 849-857 CrossRef PubMed
    • 7 Zhang, W., Mojsilovic-Petrovic, J., Andrade, M.F., Zhang, H., Ball, M. and Stanimirovic, D.B. (2003) Expression and functional characterization of ABCG2 in brain endothelial cells and vessels. FASEB J. 17, 2085-2087 PubMed
    • 8 Agarwal, S., Sane, R., Ohlfest, J.R. and Elmquist, W.F. (2011) The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain. J. Pharmacol. Exp. Ther. 336, 223-233 CrossRef PubMed
    • 9 Bauer, M., Karch, R., Zeitlinger, M., Stanek, J., Philippe, C., Wadsak, W., Mitterhauser, M., Jager, W., Haslacher, H., Muller, M. and Langer, O. (2013) Interaction of 11C-tariquidar and 11C-elacridar with P-glycoprotein and breast cancer resistance protein at the human blood-brain barrier. J. Nucl. Med. 54, 1181-1187 CrossRef PubMed
    • 10 Gutmann, H., Hruz, P., Zimmermann, C., Beglinger, C. and Drewe, J. (2005) Distribution of breast cancer resistance protein (BCRP/ABCG2) mRNA expression along the human GI tract. Biochem. Pharmacol. 70, 695-699 CrossRef PubMed
    • 11 Kruijtzer, C.M., Beijnen, J.H., Rosing, H., ten Bokkel Huinink, W.W., Schot, M., Jewell, R.C., Paul, E.M. and Schellens, J.H. (2002) Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. J. Clin. Oncol. 20, 2943-2950 CrossRef PubMed
    • 12 Maliepaard, M., Scheffer, G.L., Faneyte, I.F., van Gastelen, M.A., Pijnenborg, A.C., Schinkel, A.H., van De Vijver, M.J., Scheper, R.J. and Schellens, J.H. (2001) Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res. 61, 3458-3464 PubMed
    • 13 Woodward, O.M., Kottgen, A., Coresh, J., Boerwinkle, E., Guggino, W.B. and Kottgen, M. (2009) Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout. Proc. Natl. Acad. Sci. U.S.A. 106, 10338-10342 CrossRef PubMed
    • 14 Mao, Q. (2008) BCRP/ABCG2 in the placenta: expression, function and regulation. Pharm. Res. 25, 1244-1255 CrossRef PubMed
    • 15 Jonker, J.W., Merino, G., Musters, S., van Herwaarden, A.E., Bolscher, E., Wagenaar, E., Mesman, E., Dale, T.C. and Schinkel, A.H. (2005) The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk. Nat. Med. 11, 127-129 CrossRef PubMed
    • 16 van Herwaarden, A.E., Wagenaar, E., Merino, G., Jonker, J.W., Rosing, H., Beijnen, J.H. and Schinkel, A.H. (2007) Multidrug transporter ABCG2/breast cancer resistance protein secretes riboflavin (vitamin B2) into milk. Mol. Cell. Biol. 27, 1247-1253 CrossRef PubMed
    • 17 Basseville, A., Hall, M.D., Chau, C.H., Robey, R.W., Gottesman, M., Figg, W.D. and Bates, S.E. (2016) The ABCG2 multidrug transporter. In In ABC Transporters - 40 Years On (George, A.M., ed.), pp. 195-226, Springer, Heidelberg CrossRef
    • 18 Yoshikawa, M., Ikegami, Y., Hayasaka, S., Ishii, K., Ito, A., Sano, K., Suzuki, T., Togawa, T., Yoshida, H., Soda, H. et al. (2004) Novel camptothecin analogues that circumvent ABCG2-associated drug resistance in human tumor cells. Int. J. Cancer 110, 921-927 CrossRef PubMed
    • 19 Gozzi, G.J., Bouaziz, Z., Winter, E., Daflon-Yunes, N., Honorat, M., Guragossian, N., Marminon, C., Valdameri, G., Bollacke, A., Guillon, J. et al. (2015) Phenolic indeno[1,2-b]indoles as ABCG2-selective potent and non-toxic inhibitors stimulating basal ATPase activity. Drug Des. Dev.Ther. 9, 3481-3495
    • 20 Xu, Y., Egido, E., Li-Blatter, X., Muller, R., Merino, G., Berneche, S. and Seelig, A. (2015) Allocrite sensing and binding by the breast cancer resistance protein (ABCG2) and P-glycoprotein (ABCB1). Biochemistry 54, 6195-6206 CrossRef PubMed
    • 21 Egido, E., Muller, R., Li-Blatter, X., Merino, G. and Seelig, A. (2015) Predicting activators and inhibitors of the breast cancer resistance protein (ABCG2) and P-glycoprotein (ABCB1) based on mechanistic considerations. Mol. Pharm. 12, 4026-4037 CrossRef PubMed
    • 22 Clark, R., Kerr, I.D. and Callaghan, R. (2006) Multiple drugbinding sites on the R482G isoform of the ABCG2 transporter. Br. J. Pharmacol. 149, 506-515 CrossRef PubMed
    • 23 McDevitt, C.A., Crowley, E., Hobbs, G., Starr, K.J., Kerr, I.D. and Callaghan, R. (2008) Is ATP binding responsible for initiating drug translocation by the multidrug transporter ABCG2? FEBS J. 275, 4354-4362 CrossRef PubMed
    • 24 Ejendal, K.F., Diop, N.K., Schweiger, L.C. and Hrycyna, C.A. (2006) The nature of amino acid 482 of human ABCG2 affects substrate transport and ATP hydrolysis but not substrate binding. Protein Sci. 15, 1597-1607 CrossRef PubMed
    • 25 Robey, R.W., Honjo, Y., Morisaki, K., Nadjem, T.A., Runge, S., Risbood, M., Poruchynsky, M.S. and Bates, S. E. (2003) Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity. Br. J. Cancer 89, 1971-1978 CrossRef PubMed
    • 26 Ni, Z., Bikadi, Z., Cai, X., Rosenberg, M.F. and Mao, Q. (2010) Transmembrane helices 1 and 6 of the human breast cancer resistance protein (BCRP/ABCG2): identification of polar residues important for drug transport. Am. J. Physiol., Cell Physiol. 299, C1100-C1109 CrossRef PubMed
    • 27 Ni, Z., Bikadi, Z., Shuster, D.L., Zhao, C., Rosenberg, M.F. and Mao, Q. (2011) Identification of proline residues in or near the transmembrane helices of the human breast cancer resistance protein (BCRP/ABCG2) that are important for transport activity and substrate specificity. Biochemistry 50, 8057-8066 CrossRef PubMed
    • 28 Sissung, T.M., Baum, C.E., Kirkland, C.T., Gao, R., Gardner, E.R. and Figg, W.D. (2010) Pharmacogenetics of membrane transporters: an update on current approaches. Mol. Biotechnol. 44, 152-167 CrossRef PubMed
    • 29 Keskitalo, J.E., Zolk, O., Fromm, M.F., Kurkinen, K.J., Neuvonen, P.J. and Niemi, M. (2009) ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin. Pharmacol. Ther. 86, 197-203 CrossRef PubMed
    • 30 Kerr, I.D. (2002) Structure and association of ATP binding cassette transporter nucleotide-binding domains. Biochem. Biophys. Acta 1561, 47-64 CrossRef
    • 31 Kerr, I.D., Haider, A.J. and Gelissen, I.C. (2011) The ABCG family of membrane-associated transporters: you don't have to be big to be mighty. Br. J. Pharmacol. 164, 1767-1779 CrossRef PubMed
    • 32 Wang, H., Lee, E.W., Cai, X., Ni, Z., Zhou, L. and Mao, Q. (2008) Membrane topology of the human breast cancer resistance protein (BCRP/ABCG2) determined by epitope insertion and immunofluorescence. Biochemistry 47, 13778-13787 CrossRef PubMed
    • 33 McDevitt, C.A., Collins, R., Kerr, I.D. and Callaghan, R. (2009) Purification and structural analyses of ABCG2. Adv. Drug Deliv. Rev. 61, 57-65 CrossRef PubMed
    • 34 Rosenberg, M.F., Bikadi, Z., Chan, J., Liu, X., Ni, Z., Cai, X., Ford, R.C. and Mao, Q. (2010) The human breast cancer resistance protein (BCRP/ABCG2) shows conformational changes with mitoxantrone. Structure 18, 482-493 CrossRef PubMed
    • 35 Rosenberg, M.F., Bikadi, Z., Hazai, E., Starborg, T., Kelley, L., Chayen, N.E., Ford, R.C. and Mao, Q. (2015) Three-dimensional structure of the human breast cancer resistance protein (BCRP/ABCG2) in an inward-facing conformation. Acta. Crystallogr. D. Biol. Crystallogr. 71, 1725-1735 CrossRef PubMed
    • 36 Bai, X.C., McMullan, G. and Scheres, S.H. (2015) How cryo-EM is revolutionizing structural biology. Trends Biochem. Sci. 40, 49-57 CrossRef PubMed
    • 37 Dezi, M., Fribourg, P.F., Di Cicco, A., Arnaud, O., Marco, S., Falson, P., Di Pietro, A. and Levy, D. (2010) The multidrug resistance half-transporter ABCG2 is purified as a tetramer upon selective extraction from membranes. Biochim. Biophys. Acta 1798, 2094-2101 CrossRef PubMed
    • 38 Xu, J., Liu, Y., Yang, Y., Bates, S. and Zhang, J.T. (2004) Characterization of oligomeric human half-ABC transporter ATP-binding cassette G2. J. Biol. Chem. 279, 19781-19789 CrossRef PubMed
    • 39 Wong, K., Briddon, S.J., Holliday, N.D. and Kerr, I.D. (2015) Plasma membrane dynamics and tetrameric organisation of ABCG2 transporters in mammalian cells revealed by single particle imaging techniques. Biochim. Biophys. Acta 1863, 19-29 CrossRef PubMed
    • 40 Mo, W., Qi, J. and Zhang, J.T. (2012) Different roles of TM5, TM6, and ECL3 in the oligomerization and function of human ABCG2. Biochemistry 51, 3634-3641 CrossRef PubMed
    • 41 Nakagawa, H., Wakabayashi-Nakao, K., Tamura, A., Toyoda, Y., Koshiba, S. and Ishikawa, T. (2009) Disruption of N-linked glycosylation enhances ubiquitin-mediated proteasomal degradation of the human ATP-binding cassette transporter ABCG2. FEBS J. 276, 7237-7252 CrossRef PubMed
    • 42 Henriksen, U., Fog, J.U., Litman, T. and Gether, U. (2005) Identification of intra- and intermolecular disulfide bridges in the multidrug resistance transporter ABCG2. J. Biol. Chem. 280, 36926-36934 CrossRef PubMed
    • 43 Haider, A.J., Briggs, D., Self, T.J., Chilvers, H.L., Holliday, N.D. and Kerr, I.D. (2011) Dimerization of ABCG2 analysed by bimolecular fluorescence complementation. PLoS One 6, e25818 CrossRef PubMed
    • 44 Kage, K., Fujita, T. and Sugimoto, Y. (2005) Role of Cys-603 in dimer/oligomer formation of the breast cancer resistance protein BCRP/ABCG2. Cancer Sci. 96, 866-872 CrossRef PubMed
    • 45 Allen, J.D., van Loevezijn, A., Lakhai, J.M., van der Valk, M., van Tellingen, O., Reid, G., Schellens, J.H., Koomen, G.J. and Schinkel, A.H. (2002) Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol. Cancer Ther. 1, 417-425 CrossRef PubMed
    • 46 Allikmets, R., Schriml, L.M., Hutchinson, A., Romano-Spica, V. and Dean, M. (1998) A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res. 58, 5337-5339 PubMed
    • 47 Doyle, L.A., Yang, W., Abruzzo, L.V., Krogmann, T., Gao, Y., Rishi, A.K. and Ross, D.D. (1998) A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl. Acad. Sci. U.S.A. 95, 15665-15670 CrossRef PubMed
    • 48 Miyake, K., Mickley, L., Litman, T., Zhan, Z., Robey, R., Cristensen, B., Brangi, M., Greenberger, L., Dean, M., Fojo, T. and Bates, S.E. (1999) Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Res. 59, 8-13 PubMed
    • 49 Damiani, D., Tiribelli, M., Calistri, E., Geromin, A., Chiarvesio, A., Michelutti, A., Cavallin, M. and Fanin, R. (2006) The prognostic value of P-glycoprotein (ABCB) and breast cancer resistance protein (ABCG2) in adults with de novo acute myeloid leukemia with normal karyotype. Haematologica 91, 825-828 PubMed
    • 50 van den Heuvel-Eibrink, M.M., van der Holt, B., Burnett, A.K., Knauf, W. U., Fey, M.F., Verhoef, G.E., Vellenga, E., Ossenkoppele, G.J., Lowenberg, B. and Sonneveld, P. (2007) CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age. Ann. Hematol. 86, 329-337 CrossRef PubMed
    • 51 Damiani, D., Tiribelli, M., Geromin, A., Michelutti, A., Cavallin, M., Sperotto, A. and Fanin, R. (2015) ABCG2 overexpression in patients with acute myeloid leukemia: impact on stem cell transplantation outcome. Am.J. Hematol. 90, 784-789 CrossRef PubMed
    • 52 Kim, J.E., Singh, R.R., Cho-Vega, J.H., Drakos, E., Davuluri, Y., Khokhar, F.A., Fayad, L., Medeiros, L.J. and Vega, F. (2009) Sonic hedgehog signaling proteins and ATP-binding cassette G2 are aberrantly expressed in diffuse large B-cell lymphoma. Mod. Pathol. 22, 1312-1320 CrossRef PubMed
    • 53 Bartholomae, S., Gruhn, B., Debatin, K.M., Zimmermann, M., Creutzig, U., Reinhardt, D. and Steinbach, D. (2016) Coexpression of multiple ABC-transporters is strongly associated with treatment response in childhood acute myeloid leukemia. Pediatr. Blood Cancer 63, 242-247 CrossRef PubMed
    • 54 Benderra, Z., Faussat, A.M., Sayada, L., Perrot, J.Y., Chaoui, D., Marie, J.P. and Legrand, O. (2004) Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias. Clin. Cancer Res. 10, 7896-7902 CrossRef PubMed
    • 55 Suvannasankha, A., Minderman, H., O'Loughlin, K.L., Nakanishi, T., Ford, L.A., Greco, W.R., Wetzler, M., Ross, D.D. and Baer, M.R. (2004) Breast cancer resistance protein (BCRP/MXR/ABCG2) in adult acute lymphoblastic leukaemia: frequent expression and possible correlation with shorter disease-free survival. Br. J. Haematol. 127, 392-398 CrossRef PubMed
    • 56 Sauerbrey, A., Sell, W., Steinbach, D., Voigt, A. and Zintl, F. (2002) Expression of the BCRP gene (ABCG2/MXR/ABCP) in childhood acute lymphoblastic leukaemia. Br. J. Haematol. 118, 147-150 CrossRef PubMed
    • 57 Kourti, M., Vavatsi, N., Gombakis, N., Sidi, V., Tzimagiorgis, G., Papageorgiou, T., Koliouskas, D. and Athanassiadou, F. (2007) Expression of multidrug resistance 1 (MDR1), multidrug resistance-related protein 1 (MRP1), lung resistance protein (LRP), and breast cancer resistance protein (BCRP) genes and clinical outcome in childhood acute lymphoblastic leukemia. Int. J. Hematol. 86, 166-173 CrossRef PubMed
    • 58 Faneyte, I.F., Kristel, P.M., Maliepaard, M., Scheffer, G.L., Scheper, R.J., Schellens, J.H. and van de Vijver, M.J. (2002) Expression of the breast cancer resistance protein in breast cancer. Clin. Cancer Res. 8, 1068-1074 PubMed
    • 59 Xiang, L., Su, P., Xia, S., Liu, Z., Wang, Y., Gao, P. and Zhou, G. (2011) ABCG2 is associated with HER-2 expression, lymph node metastasis and clinical stage in breast invasive ductal carcinoma. Diagn. Pathol. 6, 90 CrossRef PubMed
    • 60 Hang, D., Dong, H.C., Ning, T., Dong, B., Hou, D.L. and Xu, W.G. (2012) Prognostic value of the stem cell markers CD133 and ABCG2 expression in esophageal squamous cell carcinoma. Dis. Esophagus 25, 638-644 CrossRef PubMed
    • 61 Li, F., Zeng, H. and Ying, K. (2011) The combination of stem cell markers CD133 and ABCG2 predicts relapse in stage I non-small cell lung carcinomas. Med. Oncol. 28, 1458-1462 CrossRef PubMed
    • 62 Ota, S., Ishii, G., Goto, K., Kubota, K., Kim, Y.H., Kojika, M., Murata, Y., Yamazaki, M., Nishiwaki, Y., Eguchi, K. and Ochiai, A. (2009) Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy. Lung Cancer 64, 98-104 CrossRef PubMed
    • 63 Tsunoda, S., Okumura, T., Ito, T., Kondo, K., Ortiz, C., Tanaka, E., Watanabe, G., Itami, A., Sakai, Y. and Shimada, Y. (2006) ABCG2 expression is an independent unfavorable prognostic factor in esophageal squamous cell carcinoma. Oncology 71, 251-258 CrossRef PubMed
    • 64 Yoh, K., Ishii, G., Yokose, T., Minegishi, Y., Tsuta, K., Goto, K., Nishiwaki, Y., Kodama, T., Suga, M. and Ochiai, A. (2004) Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer. Clin. Cancer Res. 10, 1691-1697 CrossRef PubMed
    • 65 Hirschmann-Jax, C., Foster, A.E., Wulf, G.G., Nuchtern, J.G., Jax, T.W., Gobel, U., Goodell, M.A. and Brenner, M.K. (2004) A distinct “side population” of cells with high drug efflux capacity in human tumor cells. Proc. Natl. Acad. Sci. U.S.A. 101, 14228-14233 CrossRef PubMed
    • 66 Tian, C., Ambrosone, C.B., Darcy, K.M., Krivak, T.C., Armstrong, D.K., Bookman, M.A., Davis, W., Zhao, H., Moysich, K., Gallion, H. and DeLoia, J.A. (2012) Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: a Gynecologic Oncology Group study. Gynecol. Oncol. 124, 575-581 CrossRef PubMed
  • No related research data.
  • No similar publications.

Share - Bookmark

Funded by projects

Cite this article